Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: Design, development, and place in therapy

Thomas G. Cotter, Donald M. Jensen

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the existing shortcomings in the DAA therapy spectrum. This combination has proven to be a highly efficacious pan-genotypic DAA with a high barrier to resistance as a once-daily, all-oral medication. This review explores the design and development of glecaprevir and pibrentasvir, its place in current HCV management in the midst of a myriad of DAA therapy options, and also remaining challenges.

Original languageEnglish (US)
Pages (from-to)2565-2577
Number of pages13
JournalDrug Design, Development and Therapy
Volume13
DOIs
StatePublished - 2019
Externally publishedYes

Keywords

  • Direct-acting antiviral therapy
  • Glecaprevir
  • Hepatitis C virus
  • Pibrentasvir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: Design, development, and place in therapy'. Together they form a unique fingerprint.

Cite this